Dosing begins in trial of drug combo for severe fatty liver disease
The first healthy volunteers have been dosed in a Phase 1 clinical trial testing a combination therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form…
Fatty liver disease
Liver Foundation honors family who turned diagnosis into giving
A family whose experience with biliary atresia led to an effort to help others navigate the challenges of pediatric liver disease is among those being…
A new tool may help predict your future with liver disease
One of the hardest parts of living with metabolic dysfunction-associated steatohepatitis (MASH) is carrying regrets about the past. The first time your doctor noticed…
ALF unveils network to connect living donors with strangers in need
The American Liver Foundation (ALF) is launching a first-of-its kind national database, called the ALF Living Donor Network, to connect people willing to…
Drug combo shrinks liver fat in rats and zebrafish: Study
A combination of pemafibrate and telmisartan, two medications approved in some countries to help manage cardiovascular conditions, may help reduce the buildup of liver fat…
Know your risks – and options – this National Liver Awareness Month
October is National Liver Awareness Month and Liver Cancer Awareness Month, and advocacy organizations across the U.S., including the American Liver Foundation (ALF), are…
Changes big and small can benefit those of us with MASH
This morning I woke up to a changed forest outside my window. I live in a beautiful park in Baltimore, and I bought my house…
High blood pressure may pose greatest risk of death in MASLD
High blood pressure is a leading cardiometabolic risk factor — a condition linked to problems such as heart disease, stroke, and diabetes — associated with…
A smartwatch helps me monitor symptoms of fatty liver disease
Since I learned I’d become a full-fledged metabolic dysfunction-associated steatohepatitis (MASH) patient, I’ve collected an assortment of friends with different medical issues. One of…
Roche to acquire 89bio, will get pegozafermin for MASH in deal
As part of a merger deal, Roche will acquire 89bio and its treatment candidate pegozafermin — an injection therapy now being tested in two global…
Recent Posts
- A boys’ day out brings a welcome sense of normalcy
- Rezdiffra reduces liver scarring in high-risk MASH patients: Trial data
- Used in Alagille mice, ASO therapy found to improve liver function
- Gene-editing therapy PBGENE-HBV shows encouraging trial results
- Livdelzi maintains benefits for up to 3 years in PBC: Phase 3 data